Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428589 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2ATMCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL19083691 | 0.86 | PREP (0.40) | SMN1; SMN2ATM | |
| SCHEMBL19075669 | 0.78 | PREP (0.31) | — | |
| SCHEMBL19075818 | 0.78 | PREP (0.31) | — | |
| SCHEMBL30536024 | 0.74 | PREP (0.54) | SMN1; SMN2 | |
| SCHEMBL16300621 | 0.71 | PREP (0.41) | SMN1; SMN2 | |
| SCHEMBL20333842 | 0.68 | PREP (0.39) | SMN1; SMN2 | |
| SCHEMBL993595 | 0.68 | PREP (0.39) | — | |
| SCHEMBL4040776 | 0.68 | PREP (0.39) | — | |
| SCHEMBL22555094 | 0.68 | PREP (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SMN1; SMN2 2803/4885ATM 4395/4885CHRNB2 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.